For example, the anti-VEGF agent bevacizumab, which was controversially withdrawn for metastatic breast cancer treatment by the FDA based on safety and efficacy issues44, might benefit more in early onset (<35 years) breast cancer patients since these patients clearly display upregulated circulating VEGF compared to healthy controls whereas patients >35 years have a similar or even slightly decreased plasma VEGF profile in cancer cases compared to controls. This evidence concerns the gene VEGFA and breast carcinoma.